Preimplantation  genetic    testing    for    monogenic disorders (PGT-M) and     preimplantation     genetic testing for human leukocyte antigen (PGT-HLA)   are both advanced genetic testing methods used during in vitro fertilization (IVF). PGT-M screens    embryos for single-gene disorders, such as cystic  fibrosis or sickle cell   anemia,   ensuring   that   only   embryos without  the   genetic   condition   are   selected   for implantation. PGT-HLA, on  the   other   hand,   tests embryos to identify those  that  are   compatible   as potential tissue donors for a sibling  with  a  specific genetic    condition  requiring  a  stem  cell  or  bone marrow transplant. PGT-HLA  is   typically   used   in cases    where   a    family    has    a    child   with   a  life-threatening   condition   that   could benefit from stem cell therapy. Both tests involve embryo biopsy, genetic     analysis,   and   the   selection   of healthy embryos    for    implantation.   These   technologies enhance reproductive success and offer a   way   to prevent serious genetic disorders. Together, PGT-M and PGT-HLA   provide   personalized   reproductive options   for   couples   facing   genetic   challenges.